RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Deepa Bedi to Neoplasms

This is a "connection" page, showing publications Deepa Bedi has written about Neoplasms.
Connection Strength

0.259
  1. Gunturu DR, Hassan M, Bedi D, Datta P, Manne U, Samuel T. Unlocking the Potential of Therapy-Induced Cytokine Responses: Illuminating New Pathways in Cancer Precision Medicine. Curr Oncol. 2024 02 23; 31(3):1195-1206.
    View in: PubMed
    Score: 0.116
  2. Marable J, Ruiz D, Jaiswal AK, Bhattacharya R, Pantazes R, Agarwal P, Suryawanshi AS, Bedi D, Mishra A, Smith BF, Sandey M. Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients. Sci Rep. 2021 10 21; 11(1):20763.
    View in: PubMed
    Score: 0.099
  3. Wang T, D'Souza GG, Bedi D, Fagbohun OA, Potturi LP, Papahadjopoulos-Sternberg B, Petrenko VA, Torchilin VP. Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein. Nanomedicine (Lond). 2010 Jun; 5(4):563-74.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support